Full ACACIA-HCM safety signals at ESC prompt CYTK drop

 

Full ACACIA-HCM safety signals at ESC prompt CYTK 7.18% drop

• Hot Line presentation of Phase 3 ACACIA-HCM full results occurred today at ESC Congress in Munich.
• Topline efficacy met endpoints but deltas were modest (KCCQ +3 pts, pVO2 improvement).
• Safety data showed LVEF <50% in 10% of aficamten patients vs 1% placebo, plus dose interruptions.
• Rare serious heart failure events noted, raising approvability and commercial uptake concerns for nHCM.
• High valuation and competition (e.g. Edgewise better tolerability data) amplified selling pressure.
• Builds on prior positive topline from May but details failed to excite investors per market reaction.

https://finviz.com/stock?t=CYTK&p=d